Business
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif., May 13, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today reported its first quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
About this update from Lineage Cell Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1740,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/bec8c828b6e0067f61d7d35f988e3eab"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mQFNcgZ72x5L7Ec_QDyW6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bec8c828b6e0067f61d7d35f988e3eab","width":960,"height":199},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/8d1EImXnEKEOI5iEFiqQ1Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/bec8c828b6e0067f61d7d35f988e3eab","width":1200,"height":248}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to be featured June 21st at Clinical Trials at the Summit 2025","length":123,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Initiated Clinical Study of OPC1 Delivery Device for Patients with Subacute and Chronic Spinal Cord Injury","length":106,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced 3rd Annual SCI Investor Symposium with Christopher & Dana Reeve Foundation","length":88,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":317,"olType":false},{"type":"text","content":"CARLSBAD, Calif., May 13, 2025--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, today reported its first quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.","length":467,"tagName":"p"},{"type":"text","content":""Lineage has grown increasingly confident in OpRegen’s potential to address a significant medical need," stated Brian M. Culley, Lineage CEO. "Our optimism is driven in part by OpRegen’s uniquely durable treatment effects, lasting up to 24 months, with a 36-month data update from Roche and Genentech forthcoming next month. We are also encouraged by independent first-in-human results recently reported by competitors, which adds validation to a...